TABLE 2.
Effect of taf130/145 allele on ADR1-TAD activationa
| Genotype | LexA fusion | Mean β-Galactosidase activity (U/mg) ± SEM | Fold decrease |
|---|---|---|---|
| Wild type | LexA-TADIV | 171 ± 32 | 4.3 |
| taf130/145 | LexA-TADIV | 40 ± 5.7 | |
| Wild type | LexA-B42 | 160 ± 18 | 1.0 |
| taf130/145 | LexA-B42 | 160 ± 27 | |
| Wild type | LexA-TADIII | 42 ± 4.9 | 1.4 |
| taf130/145 | LexA-TADIII | 30 ± 5.4 | |
| Wild type | LexA-TADII | 110 ± 7.1 | 1.7 |
| taf130/145 | LexA-TADII | 66 ± 12 |
a
β-Galactosidase activities were determined as described previously (12) on at least five separate transformants following growth in glucose-containing medium at the permissive temperature of 30°C. The p1840 reporter plasmid used contains one LexA operator upstream of the lacZ gene (12). LexA-TADIV contains residues 642 to 704 of ADR1 fused to LexA-202, LexA-B42 consists of the E. coli-derived B42 activator, LexA-TADIII contains residues 420 to 462 of ADR1, and LexA-TADII consists of residues 263 to 359 of ADR1 (12).